Audit to Evaluate Recurrence Rates in Patients with DCIS Treated with Adjuvant Radiotherapy and the Role of Endocrine Treatment

Purpose: Ductal carcinoma-in-situ (DCIS) comprises 20 –25% of screening detected breast cancers [1], with a low 20-year mortality rate of 3% [2]. Radiotherapy has been found to halve the likelihood of recurrence, versus breast-conserving surgery (BCS) alone, to 15% at 10 years [3–5]. There is conflicting evidence if endocrine therapy gives a signif icant benefit in patients treated with BCS and radiotherapy [6,7]. Furthermore, endocrine therapy can cause significant morbidity and up to 20% of patients do not tolerate the full course of treatment [8].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research